Genzyme and Bone Care International Announce Completion of Hart-Scott-Rodino Review
17-Jun-2005
As announced on May 4, 2005, Genzyme and Bone Care have signed a definitive merger agreement under which Genzyme will acquire Bone Care in an all cash transaction valued at $33.00 per fully diluted share. The transaction remains subject to approval by Bone Care's shareholders at a meeting on June 30, and other customary closing conditions.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Sunflower
Go to page
List_of_geometrid_genera:_F
Go to page
List_of_lymantriid_genera:L
Go to page
Cardiac_surgery
Go to page
List_of_arctiid_genera:_W
Go to page
Kyoho_grape
Go to page
Characterization of grapevine transposons furthers understanding of in vino variety
Go to page
Santhera initiates Pivotal Phase III Study with Catena/Sovrima (Idebenone) in Duchenne Muscular Dystrophy
Go to page
Rehabilitation_(neuropsychology)
Go to page
MediGene reports positive results for the first half of 2011 and confirms forecast for the year - Increase in total revenue (from continued operations and discontinued operations) by 18% to EUR 29.6 million (6M 2010: EUR 25.2 million)
Go to page
Singapore - Europe's access to Asia
Go to page
AMT Successful in Preclinical Treatment of DMD
Go to page